A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors [clinicaltrials:NCT01714739]

Bio2RDF identifier

NCT01714739

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01714739

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01714739

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

162

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01714739 arm group 3f29a3bd8853706249cd4b2c77d07f32 [clinicaltrials_resource:NCT01714739/arm-group/3f29a3bd8853706249cd4b2c77d07f32]

NCT01714739 arm group 6d92f6c0154f3f108b49b425f17c7ed5 [clinicaltrials_resource:NCT01714739/arm-group/6d92f6c0154f3f108b49b425f17c7ed5]

NCT01714739 arm group 848de2a5a4e74547b55031b7d43a46f7 [clinicaltrials_resource:NCT01714739/arm-group/848de2a5a4e74547b55031b7d43a46f7]

NCT01714739 arm group a09b77ebdbf020aa345b270fddd506bd [clinicaltrials_resource:NCT01714739/arm-group/a09b77ebdbf020aa345b270fddd506bd]

NCT01714739 arm group ebbb522daa43864a88f3d7007f4c9614 [clinicaltrials_resource:NCT01714739/arm-group/ebbb522daa43864a88f3d7007f4c9614]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... r unresectable) solid tumors.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Phase I Study of an Anti-KIR ...... nts With Advanced Solid Tumors

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:42a22ae056e2cbfbc87cff037ef240ea]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:b64d31c7fcdd07d10006043ed16b9f59]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:04b3802ca0d3d47a3fbf7158803492b0]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:174a4bfd4865de5e6ae27941bfa6961b]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:2f3070ab8085cc8593956c421e3e3a76]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:315508e60e2387c74738b846a00abb6d]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:4628c6417426d151be7d725375795237]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:4f6143165f6fb08872b17c6078d5a1cf]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:53df646de4186350633f961e7d4a03d8]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:6c0463779a588562f5cf15c9daec9a0b]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:71fdbcc74e99adafd7df19b388e4da60]

Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:88058392a75296070cc29121800a1fcc]

completion date [clinicaltrials_vocabulary:completion-date]

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

CANCER,NOS [clinicaltrials_resource:c02e913b926cc5ce342743a4037dab58]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01714739 [clinicaltrials_resource:8ebd96606a8f8dfaa0b239ebc3be3803]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Lirilumab [clinicaltrials_resource:15b32ab8ee031482b75f4c68faeb43ec]

Nivolumab [clinicaltrials_resource:3829f092a3942b43526cfe0a4059bb56]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

nct id [clinicaltrials_vocabulary:nct-id]

NCT01714739

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

5

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 1 Dose Escalation and ...... nts With Advanced Solid Tumors

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CA223-001

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Bristol-Myers Squibb [clinicaltrials_resource:3198a154b3c6ab71c470cee213664836]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Bristol-Myers Squibb [clinicaltrials_resource:8dd8033e871f3c82c52377f2b0914757]

overall official [clinicaltrials_vocabulary:overall-official]

Bristol-Myers Squibb [clinicaltrials_resource:d3a813b7ce44062a0bf05c46ffe9add7]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:b59a42cee4da471f6477af3987e51e96]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

start date [clinicaltrials_vocabulary:start-date]

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01714739 study design [clinicaltrials_resource:45fb311e7cb1599be09a89104c314e12]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01714739

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01714739

http://www.w3.org/2001/XMLSchema#string

title

A Phase I Study of an Anti-KIR ...... nts With Advanced Solid Tumors

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Phase I Study of an Anti-KIR ...... s [clinicaltrials:NCT01714739]

@en